Nghĩa của từ T dependent antigen bằng Tiếng Việt
danh từ
kháng nguyên phụ thuộc T
Đặt câu có từ "T dependent antigen"
1. T-Cell Clonality; T cell antigen receptors, Gene Rearrangement; Laboratory
2. Chimeric Antigen Receptor (CAR) T-cell Therapy
3. Adoptive T-cell therapies with T-cells modified with chimeric antigen receptors (CAR-T) also causes CRS.
Điều trị miễn dịch ung thư bằng tế bào T đã được sửa đổi có các thụ thể kháng nguyên chimeric (CAR-T) cũng gây ra CRS.
4. As with B cells, each type of T cell recognizes a different antigen.
Giống như các tế bào B, mỗi loại tế bào T nhận ra một kháng nguyên khác nhau.
5. An Antigen-specific B cell antibody specifically recognizes a TI-2 Antigen, but without T cell help, a memory response is not seen.
6. Chimeric antigen receptor (CAR) T-cell therapy represents a major advancement in personalized cancer treatment. In this strategy, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen.
7. 13 Chromatin (or nucleosomes) is an antigen for T and B cells from patients with SLE
8. Enhancements in the Cytotoxic activity of tumor antigen-specific Cytotoxic T cells in the tumor microenvironment are
9. SAg stimulation of Antigen presenting cells and T-cells elicits a response that is mainly inflammatory, focused on the action of Th1 T-helper cells
10. Conclusion The development of microvolt T-wave alternans is highly dependent on heart rate.
11. How Cytotoxic T cells get activated by MHC-I/antigen complexes and then proceed to kill infected cells
12. Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell
13. The Company develops Allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors.
14. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T-cell (CAR T
15. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T
16. Upon contact with its specific antigen, the T cell receptor transduces an activation signal into the T cell, leading to proliferation, cytokine production, or efficient cytotoxicity.
17. Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors
18. Precipitation occurs with univalent antigen, whereas Agglutination requires multivalent antigen
19. For Cell mediated rejection, T cells require multiple signals for activation, the minimum being two signals; antigen recognition and costimulation
20. Infusion of T lymphocytes expressing Chimeric antigen receptors (CARs) can produce extraordinary antitumor activity in patients with leukemia, lymphoma, and myeloma
21. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer
22. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of Allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer
23. What she doesn t see is that her small-business world is dependent on a bigger economic system.
24. Anti-inflammatory, skin-regenerative, whitening, antioxidant, or wound-healing composition containing culture medium of adsc-t cells in which t-antigen is introduced into adipose-derived stem cell as active ingredient
25. Although not confirmed as yet, this system presumably will be where naive (unstimulated) T cells accumulate while waiting to encounter an antigen.